← All topics

Industry, profession & meta

Vertical-specific research

27 indexed claims · 7 guests · peaked 2025-Q2

Vertical-specific research

Overview

These conversations reveal what the general market research discourse tends to understate: that vertical context doesn't merely modify research practice — it often inverts it. In healthcare and pharma, the person in the room is rarely the customer, the person signing the contract rarely the buyer, and the clinician making life-affecting decisions rarely a free agent. In telecom, hardware commoditization has made the device itself a vehicle rather than a destination. Across these industries, the guests represented here circle the same cluster of tensions: how fast can you responsibly move, who must be included to get the intelligence right, and how much of what AI promises is genuine capability versus transplanted hype from less-regulated contexts. Their shared argument is that vertical depth isn't specialization — it's epistemology.

From the corpus

  • Synthetic or simulated respondent data in pharma is not yet trustworthy for primary research decisions; the bar for adoption should be a properly controlled side-by-side comparison — same survey design, same questions, real vs. synthetic participants, with the training provenance of the synthetic sample disclosed. — Shawn McKenna, Ep. 9 · cl-shawn-mckenna-010
  • In healthcare market intelligence, the customer is rarely the person in front of you and the buyer rarely the person signing the contract — clinical outcomes are shaped by economic, social, technological, and policy stakeholders with conflicting incentives, and intelligence systems must hold all of them at once. — Christopher Khoury, Ep. 47 · cl-christopher-khoury-005
  • AI has not produced compelling use cases in pharma primary research and survey design; NLP-based open-end coding dates to the 1970s, AI-designed surveys miss clinical nuance, and the productivity gains in AI-assisted data categorization still require human supervision of the output. — Shawn McKenna, Ep. 9 · cl-shawn-mckenna-008
  • Smartphone upgrade cycles have lengthened significantly because hardware has reached a point of diminishing marginal return — consumers no longer perceive meaningful differences between generations, so the two-year device-lock model that anchored telecom retention is obsolete. — Subhasish Nanda, Ep. 17 · cl-subhasish-nanda-005
  • Stop assuming new technological implementations are slam-dunk productivity wins — the people who do the work are the most valuable asset, and the seductive promise of a productivity-frontier step-change must be evaluated for the harm it does to them first. — Christopher Khoury, Ep. 47 · cl-christopher-khoury-017
  • Forecasting accuracy depends on identifying the actual decision-maker behind a purchase, not the most visible audience: pharma needs the consumer, the prescribing doctor, AND managed care; men's cologne needs to interview women who buy 70% of it. — Charlie Grossman, Ep. 34 · cl-charlie-grossman-019
  • Large institutions are aircraft carriers and startups are speedboats — both are boats, but docking them is the real work; the dialogue is more valuable than the corporate partnership that may not materialize. — Christopher Khoury, Ep. 47 · cl-christopher-khoury-007
  • AI in healthcare is a sociotechnical system, not a set of products — the technologies operate inside complex social environments and require different questions than purely technical evaluation supplies. — Christopher Khoury, Ep. 47 · cl-christopher-khoury-011

Contributing guests

Episodes in Vertical-specific research

See Industry, profession & meta mapped across all quarters →